Adverse events ‐ pneumonia · critically ill adults admitted to the ICU for trauma, emergency, or post‐surgical care; population excludes participants with acute…
Enteral showed no clear difference in adverse events: pneumonia (as reported by study authors at end of… compared with parenteral nutrition (low certainty).
1 finding from 1 review
Adverse events: aspiration (as reported by study authors at end of study · critically ill adults admitted to the ICU for trauma, emergency, or post‐surgical care; population excludes participants with acute…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: aspiration (as reported by study authors at end of study · critically ill adults admitted to the ICU for trauma, emergency, or post‐surgical care; population excludes participants with acute…
It is very uncertain whether enteral changes adverse events: aspiration (as reported by study authors at end of… compared with parenteral nutrition (very low certainty).
1 finding from 1 review
Adverse events (3‐week to 1‐year · Adults with COPD
Once‐daily LABA/LAMA in a combined inhaler showed no clear difference in adverse events (3‐week to 1‐year compared with placebo (high certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in non‐fatal serious adverse events compared with formoterol (moderate certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in non‐fatal serious adverse events compared with aclidinium alone (moderate certainty).
1 finding from 1 review
Adverse effects (weeks 0 to 26): serious infection requiring hospitalisation · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in adverse events (weeks 0 to 26): serious infection requiring… compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
Adverse events ‐ Nephrolithiasis in trials using vitamin D3 combined with calcium · healthy participants or recruited among the general population; individuals diagnosed with a specific disease in a stable phase or with…
Vitamin D may leads to higher adverse events: nephrolithiasis in trials using vitamin… compared with placebo or no intervention (low certainty).
1 finding from 1 review
Serious adverse events (3‐week to 1‐year · Adults with COPD
Once‐daily LABA/LAMA in a combined inhaler showed no clear difference in serious adverse events (3‐week to 1‐year compared with placebo (high certainty).
1 finding from 1 review
Adverse events—any Duration of two years1 · COPD
Fluticasone/salmeterol (FPS) showed no clear difference in adverse events—any Duration of two years1 compared with placebo (low certainty).
1 finding from 1 review
OR 1.09 [0.95, 1.25]
5574 participants
Low
Incidence of adverse events at 3 months of · people with meibomian gland dysfunction
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Adverse events—'serious' Duration of two years1 · COPD
Fluticasone/salmeterol (FPS) showed no clear difference in adverse events—'serious' Duration of two years1 compared with placebo (low certainty).
1 finding from 1 review
OR 1.08 [0.95, 1.23]
5531 participants
Low
Intervention not reported
Adverse events (number of adverse events/person/year) · adults (> 18 years of age) with either COPD or recurrent acute exacerbations of chronic bronchitis
The intervention showed no clear difference in adverse events (number of adverse events/person/year) (low certainty).
1 finding from 1 review
Adverse events—'serious'—320/94 Duration of 10 months3 · COPD
Budesonide/formoterol (BDF) showed no clear difference in adverse events—'serious'—320/94 Duration of 10 months3 compared with placebo (low certainty).
1 finding from 1 review
OR 1.17 [0.95, 1.45]
2476 participants
Low
Intervention not reported
Serious adverse events ‐ Haemodilution versus control. · patients with liver resection.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (disease‐related: all physical symptoms); · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review
Participants with at least some Side Effects · community‐dwelling older adults ≥ 65 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events—'serious'—160/94 Duration of nine months 3 · COPD
Budesonide/formoterol (BDF) showed no clear difference in adverse events—'serious'—160/94 Duration of nine months 3 compared with placebo (low certainty).
1 finding from 1 review
OR 1.2 [0.89, 1.63]
1556 participants
Low
Adverse events (timing not specified) · exacerbations of COPD
Antibiotics showed no clear difference in adverse events ‐ overall (any adverse events not specified) compared with placebo overall (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events, any (endpoints fall between 1 6 six months) · Any individual experiencing recurrent aggressive outbursts or episodes
1 finding from 1 review